Knockdown of ZNF529-AS1 expression may improve the sensitivity to targeted drug therapy for HCC, promote the activation of the body’s immune system, inhibit the occurrence and development of HCC, enhance clinical efficacy, and improve patient prognosis. The gene discussed is ZNF529; the disease is hepatocellular carcinoma.